Abstract: |
Limitations in current imaging tools have long challenged the imaging of small pancreatic islets in animal models. Here, we report the first development and in vivo validation testing of a broad-spectrum and high-absorbance near-infrared optoacoustic contrast agent, E4x12-Cy7. Our near-infrared tracer is based on the amino acid sequence of exendin-4 and targets the glucagon-like peptide-1 receptor (GLP-1R). Cell assays confirmed that E4x12-Cy7 has a high-binding affinity (dissociation constant, Kd, 4.66 0.8 nM). Using themultispectral optoacoustic tomography, we imaged E4x12-Cy7 and optoacoustically visualized b-cell insulinoma xenografts in vivo for the first time. In the future, similar optoacoustic tracers that are specific for b-cells and combines optoacoustic and fluorescence imaging modalities could prove to be important tools for monitoring the pancreas for the progression of diabetes. © 2021 Society of Nuclear Medicine Inc.. All rights reserved. |